Conference Reports for NaTaP

EASL - The International Liver Congress 2015 50th annual Meeting of the European association for the Study of the Liver Vienna, austria  april 22-26 Back

Pharmacokinetics of ABT-493 and ABT-530 is Similar in Healthy Caucasian, Han Chinese, and Japanese Adult Subjects       Reported by Jules Levin EASL 2015 April 22-26 Vienna Austria   Tianli Wang1, Wei Liu2, Armen Asatryan3, Jingtao Wu2, Andrew Campbell3, Jens Kort3, Sandeep Dutta2 1Former AbbVie employee, Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, USA 2Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, USA 3HCV Clinical Development, AbbVie, North Chicago, IL, USA   ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage...... http://www.natap.org/2014/CROI/croi_14.htm   A Next Generation HCV DAA Combination: Potent, Pangenotypic Inhibitors ABT-493 and ABT-530 With High Barriers to Resistance...... http://www.natap.org/2014/AASLD/AASLD_51.htm   ABT-530, an HCV NS5A Inhibitor With Potent Pangenotypic Activity and High Genetic Barrier to Resistance..... http://www.natap.org/2014/CROI/croi_11.htm